(Q37779319)

23 August 2017

1 reference

title

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies (English)

1 reference

23 August 2017

1 reference

1 reference

1 reference

David M Burger

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1151-1160

1 reference

Emerging pharmacology: inhibitors of human immunodeficiency virus integration

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

The effect of raltegravir on the glucuronidation of lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Raltegravir-based HAART regimen in a patient with large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Severe rhabdomyolysis associated with raltegravir use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

A case of rhabdomiolysis associated with raltegravir use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Lack of a significant drug interaction between raltegravir and tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Effects of omeprazole on plasma levels of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.513383

10.1517/17425255.2010.513383

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference